Autophagy in peritoneal fibrosis [PDF]
Frontiers in Physiology, 2023 Peritoneal dialysis (PD) is a widely accepted renal replacement therapy for patients with end-stage renal disease (ESRD). Morphological and functional changes occur in the peritoneal membranes (PMs) of patients undergoing long-term PD.
Hong-yong Su +8 more
doaj +6 more sources
Preventing Peritoneal Dialysis-Associated Fibrosis by Therapeutic Blunting of Peritoneal Toll-Like Receptor Activity [PDF]
Frontiers in Physiology, 2018 Peritoneal dialysis (PD) is an essential daily life-saving treatment for end-stage renal failure. PD therapy is limited by peritoneal inflammation, which leads to peritoneal membrane failure as a result of progressive fibrosis.
Anne-Catherine Raby, Mario O. Labéta
doaj +6 more sources
Inhibition of calpain9 attenuates peritoneal dialysis-related peritoneal fibrosis
Frontiers in Pharmacology, 2022 Aim: Peritoneal dialysis is a common renal replacement method for end-stage renal disease. Long-term peritoneal dialysis leads to peritoneal dialysis-related peritoneal fibrosis, which leads to a cessation of treatment.
Fang Li +9 more
doaj +4 more sources
The Gut-Peritoneum Axis in Peritoneal Dialysis and Peritoneal Fibrosis [PDF]
Kidney Medicine, 2023 Peritoneal fibrosis is an important cause of peritoneal dialysis (PD) discontinuation worldwide and is associated with high morbidity and mortality rate.
Natalia Stepanova
doaj +4 more sources
Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. [PDF]
PLoS ONE, 2014 Fibrosis is a significant health problem associated with a chronic inflammatory reaction. The precise mechanisms involved in the fibrotic process are still poorly understood.
Guadalupe T González-Mateo +8 more
doaj +17 more sources
Peritoneal fibrosis: from pathophysiological mechanism to medicine [PDF]
Frontiers in PhysiologyPeritoneal dialysis (PD) is currently one of the effective methods for treating end-stage renal disease (ESRD). However, long-term exposure to high concentration glucose in peritoneal dialysis environment could lead to peritoneal fibrosis (PF), impaired ...
Yingxi Kang, Yuan Liu, Ping Fu, Liang Ma
doaj +4 more sources
Український Журнал Нефрології та Діалізу, 2022 Peritoneal dialysis (PD) leads to structural and functional changes in the peritoneal membrane, the endpoint of which is peritoneal fibrosis. Peritoneal fibrosis is diagnosed in 50% and 80% of PD patients within 1 and 2 years of treatment initiation ...
N. Stepanova, L. Snisar, O. Burdeyna
doaj +3 more sources
Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis [PDF]
PharmaceuticalsBackground/Objectives: Long-term peritoneal dialysis (PD) often results in peritoneal damage and fibrosis, impairing peritoneal membrane function and leading to ultrafiltration failure.
Chiao-Yin Sun +3 more
doaj +2 more sources
Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal dialysis [PDF]
, 2015 Peritoneal dialysis (PD) is a form of renal replacement therapy whose repeated use can alter dialytic function through induction of epithelial-mesenchymal transition (EMT) and fibrosis, eventually leading to PD discontinuation. The peritoneum from Cav1-/-
Enrique, Calvo +13 more
core +2 more sources
Integrating single-cell RNA-seq, bulk RNA-seq and network pharmacology reveals protective effect of salidroside in peritoneal dialysis-associated peritoneal fibrosis [PDF]
Frontiers in PharmacologySalidroside (2- (4-Hydroxyphenyl) ethyl β-D-glucopyranoside, SAL) is a bioactive compound present in Rhodiola rosea L., exhibiting diverse pharmacological properties such as anti-inflammatory and anti-fibrotic effects.
Shuting Li +10 more
doaj +2 more sources